136 related articles for article (PubMed ID: 2440107)
1. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
Daley GQ; McLaughlin J; Witte ON; Baltimore D
Science; 1987 Jul; 237(4814):532-5. PubMed ID: 2440107
[TBL] [Abstract][Full Text] [Related]
2. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
Ben-Neriah Y; Daley GQ; Mes-Masson AM; Witte ON; Baltimore D
Science; 1986 Jul; 233(4760):212-4. PubMed ID: 3460176
[TBL] [Abstract][Full Text] [Related]
3. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
4. Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.
Rees-Jones RW; Goff SP
J Virol; 1988 Mar; 62(3):978-86. PubMed ID: 2828693
[TBL] [Abstract][Full Text] [Related]
5. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
Daley GQ; Baltimore D
Proc Natl Acad Sci U S A; 1988 Dec; 85(23):9312-6. PubMed ID: 3143116
[TBL] [Abstract][Full Text] [Related]
6. The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
Lugo TG; Witte ON
Mol Cell Biol; 1989 Mar; 9(3):1263-70. PubMed ID: 2725497
[TBL] [Abstract][Full Text] [Related]
7. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
Franz WM; Berger P; Wang JY
EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
[TBL] [Abstract][Full Text] [Related]
8. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Hariharan IK; Adams JM; Cory S
Oncogene Res; 1988; 3(4):387-99. PubMed ID: 3147434
[TBL] [Abstract][Full Text] [Related]
9. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
Zhao RC; Jiang Y; Verfaillie CM
Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
LaMontagne KR; Hannon G; Tonks NK
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14094-9. PubMed ID: 9826659
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Burgess GS; Williamson EA; Cripe LD; Litz-Jackson S; Bhatt JA; Stanley K; Stewart MJ; Kraft AS; Nakshatri H; Boswell HS
Blood; 1998 Oct; 92(7):2450-60. PubMed ID: 9746785
[TBL] [Abstract][Full Text] [Related]
12. Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.
Yi CR; Rosenberg N
J Virol; 2007 Sep; 81(17):9461-8. PubMed ID: 17596313
[TBL] [Abstract][Full Text] [Related]
13. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
14. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
15. Gag-derived but not abl-derived determinants are exposed on the surface of Abelson virus-transformed cells.
Schiff-Maker L; Rosenberg N
Virology; 1986 Oct; 154(2):286-301. PubMed ID: 3020782
[TBL] [Abstract][Full Text] [Related]
16. Baculovirus expression of functional P210 BCR-ABL oncogene product.
Pendergast AM; Clark R; Kawasaki ES; McCormick FP; Witte ON
Oncogene; 1989 Jun; 4(6):759-66. PubMed ID: 2499863
[TBL] [Abstract][Full Text] [Related]
17. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
19. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
20. Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.
Naldini L; Stacchini A; Cirillo DM; Aglietta M; Gavosto F; Comoglio PM
Mol Cell Biol; 1986 May; 6(5):1803-11. PubMed ID: 2431286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
